| Wockhardt, Sun get US okay for generic drug | 19-NOV-09 |
|
| Indian drug companies Wockhardt and Sun Pharmaceutical Industries have received final approval from the United States Food and Drug Administration (USFDA) to market generic versions of Nicardipine, the hypertension drug. |
|
|
|
|
|
|
| HC stops Zydus drug sale on Sun petition | 11-NOV-09 |
|
| The Madras High Court today directed Ahmedabad-based Zydus Cadila (Cadila Healthcare) not to sell its anti-depressant drug, Venz (venlafaxine), in the domestic market for the time being, based on a trademark complaint from Mumbai-based Sun Pharmaceutical industries. |
|
|
|
|
|
|
| Sun Pharma net profit dips 11.5% | 29-OCT-09 |
|
| Sun Pharmaceutical Industries, India’s largest drug firm in terms of market capitalisation, posted a 11.49 dip in net profit during the quarter ended September 30, compared with the same period last year, due to regulatory issues and the resultant loss of revenue for its US subsidiary, Caraco Pharmaceuticals. |
|
|
|
| Sun Pharma rises 2.3% on nod for generic drug | 06-OCT-09 |
|
| Sun Pharmaceutical Industries scrip rose Rs 32 or 2.3 per cent to close the day at Rs 1,429.20 on reports of US Food and Drug Administration’s (USFDA’s) nod for a generic drug. |
|
|
|
| Sensex may be on course to 18k | 04-OCT-09 |
|
| The Sensex ended the holiday-shortened week by gaining 442 points due to the prevailing positive sentiment. While the index touched a fresh 16-month high of 17,196, it also reclaimed the 17,000-mark for two consecutive days on a closing basis. |
|
|
|
| Caraco agrees to undertake action to get USFDA ban lifted | 01-OCT-09 |
|
| Sun Pharma's US-based subsidiary Caraco Pharmaceuticals has agreed to undertake a series of measures as per requirements of the US health regulator Food and Drug Administration (FDA) to get a ban on its manufacturing units lifted. |
|
|
|
|
|
|
| Taro files lawsuit against Sun in US | 30-SEP-09 |
|
| Israeli drug firm Taro Pharmaceuticals has filed a law suit in a US district court against Mumbai-based Sun Pharmaceutical Industries alleging violation of non-disclosure agreement and misleading shareholders. |
|
|
|
| Markets piggy back on global cues | 29-SEP-09 |
|
| The Dow Jones had rallied overnight on news of positive global cues. And as if on cue, the sun rose on the Asian bourses as well. The positive sentiment, inevitably, rubbed off on our markets. The Sensex opened with a positive gap of 136 points at 16,829. The markets thereafter went into hibernation, trading in a narrow range of 100 points between a high of 16,907 points and a low of Rs 16,802. It finally ended at 16, 852, up 159 points. |
|
|
|
| Sun, Caraco to file 30 marketing applications for generics | 17-SEP-09 |
|
| Sun Pharmaceutical Industries and its troubled US subsidiary, Caraco Pharmaceuticals, plan to together file 30 Abbreviated New Drug Applications with the US Food and Drug Administration (FDA) to market generic drugs, despite regulatory issues for the US company. |
|
|
|
|
|
|
|
|
|
| Sun Pharma settles patent dispute with Astra Zeneca | 04-AUG-09 |
|
| Sun Pharmaceutical Industries has settled a patent dispute with MedImmune, a unit of drug major Astra Zeneca, to dismiss an ongoing litigation in a US District Court. This was on patent rights of Ethyol (amifostine), a drug used to reduce toxicities associated with chemotherapy and radiation in head and neck cancers. |
|
|
|
Content Guide
